The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as "rarely appropriate," "uncertain," or "appropriate." Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. Conclusion: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer’s disease.

阿尔茨海默病协会和核医学与分子影像学会召集了一个多学科工作组，以更新淀粉样蛋白正电子发射断层扫描 （PET） 的适当使用标准 （AUC），并开发 tau PET 的 AUC。方法：该工作组确定了指导临床淀粉样蛋白/tau PET 系统文献综述的关键研究问题。在此综述的基础上，工作组制定了 17 种可以考虑淀粉样蛋白或 tau PET 的临床情况。使用修改后的 Delphi 方法将每种情景一致评为“很少合适”、“不确定”或“适当”。淀粉样蛋白和 tau PET 作为独立模式分别进行评级。结果：对于淀粉样蛋白 PET，7 种情况被评为适当，2 种为不确定，8 种为很少合适。对于 tau PET，5 种情况被评为适当，6 种为不确定，6 种为很少合适。结论：淀粉样蛋白和 tau 蛋白 PET 的 AUC 为这些技术在不断发展的阿尔茨海默病诊断和治疗领域的临床应用提供了专家建议。